Menu
Montecito
PacPremier
Loading...
You are here:  Home  >  'drug'  -  Page 6
Latest

Amgen tax hit lowers net income 74 percent for 2017

By   /  Thursday, February 1st, 2018  /  Central Coast Health Watch, Earnings, East Ventura County, Technology, Tri-County Public Companies  /  Comments Off on Amgen tax hit lowers net income 74 percent for 2017

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen lawsuit over cholesterol drug will get new trial

By   /  Thursday, October 5th, 2017  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on Amgen lawsuit over cholesterol drug will get new trial

An Amgen lawsuit against a competing cholesterol drug will get a new trial but sales of the drug will be allowed in the U.S. until a decision is rendered. A federal court of appeals judge threw out a ban on the sale of Praluent, manufactured by New York-based Regeneron Pharmaceuticals and French biotech company Sanofi Read More →

Read More →
Latest

Amgen partnering to develop new drugs

By   /  Friday, July 21st, 2017  /  Central Coast Health Watch, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Amgen partnering to develop new drugs

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

FDA gives full approval to Amgen leukemia drug Blincyto

By   /  Tuesday, July 11th, 2017  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA gives full approval to Amgen leukemia drug Blincyto

Amgen’s leukemia drug Blincyto received full approval from the U.S. Food and Drug Administration on July 11 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children. The biotech giant, headquartered in Thousand Oaks, had previously announced that the drug had been fast-tracked for priority review. The full approval includes data Read More →

Read More →
Latest

FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease

By   /  Tuesday, February 7th, 2017  /  Central Coast Health Watch, Latest news  /  Comments Off on FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease

The U.S. Food and Drug Administration approved Amgen’s Parsabiv drug to treat patients with chronic kidney disease, the company announced on Feb. 7. The Thousand Oaks-based biotech company’s Parsabiv is the first therapy approved for the treatment of secondary hyperparathyroidism for patients on hemodialysis in 12 years, Amgen said. “We are excited about today’s approval Read More →

Read More →
Latest

Settlement ends Amgen drug kickback saga

By   /  Thursday, January 7th, 2016  /  Central Coast Health Watch, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Settlement ends Amgen drug kickback saga

A drug kickback program is finally behind Amgen, the Thousand Oaks-based pharmaceutical giant. Louisville, K.Y.-based PharMerica was the last of three companies to settle lawsuits relating to Amgen allegedly paying kickbacks to PharMerica and another company to prescribe patients the anemia drug Aranesp. PharMerica settled the suit for $2.5 million in December, Louisville Business First Read More →

Read More →